Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Bland, low-fat, low-fiber foods are usually best for calming Wegovy-related diarrhea, including bananas, white rice, applesauce, plain toast, crackers, potatoes, oatmeal, and skinless chicken or fish. Sipping water, broth, or electrolyte drinks throughout the day helps replace lost fluids, while greasy, fried, spicy, very sugary, and high-fiber foods along with dairy, alcohol, and caffeine tend to make symptoms worse. Smaller, more frequent meals eaten slowly are often easier to tolerate than large portions, and symptoms commonly ease as your body adjusts or between dose increases. Several important factors affect what works for you, including your dose, other medications, and warning signs like fever, blood in stool, severe pain, or dehydration that need prompt medical attention. See below to understand more before changing your diet or your medication routine.
Because diarrhea on Wegovy can look like a harmless adjustment period or signal something that needs treatment, it helps to sort out which one you are dealing with before waiting it out. A free, instant, online symptom check asks about your symptoms, timing, and severity, then helps you understand possible causes and what to do next. It takes only a few minutes, costs nothing, and can give you clearer language to bring to your prescriber if your symptoms are not settling.
Last reviewed for medical accuracy: 09/14/2026
What to Eat to Stop Diarrhea While You’re on Wegovy
Starting Wegovy (semaglutide) can help with weight management, but some people notice digestive changes—diarrhea being one of the most common. Understanding why does Wegovy cause diarrhea and knowing which foods can help calm your gut will make managing these side effects easier.
Wegovy is a GLP-1 receptor agonist. It works by:
These changes can:
All of this can lead to loose stools or diarrhea, especially during dose increases.
Persistent diarrhea can lead to dehydration, nutrient deficiencies and electrolyte imbalances. If you experience any of the following, talk to your doctor right away:
You can also try a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify your symptoms and next steps.
Always follow up with your healthcare provider before making major changes to your diet or if you suspect a serious issue.
Diarrhea on Wegovy can be unpleasant, but it often improves as your body adjusts. A diet focused on bland, easily digestible foods, adequate hydration and small, frequent meals gives your gut the best chance to settle. Keep track of what works for you, and don’t hesitate to
speak to a doctor about anything that could be life threatening or serious.
Sticking with these strategies and checking in when you need extra help can make your Wegovy experience more comfortable—and more successful in the long run.
(References)
* Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. PMID: 28110911.
* Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. PMID: 33625476; PMCID: PMC7905697.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J, Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004. doi: 10.2337/dc22-1710. PMID: 36857477; PMCID: PMC10154650.
* Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024 Apr 15;25(8). doi: 10.3390/ijms25084346. Epub 2024 Apr 15. PMID: 38673931; PMCID: PMC11050669.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* de Paiva IHR, da Silva RS, Mendonça IP, de Souza JRB, Peixoto CA. Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacol. 2024 Jul 23;19(1):36. doi: 10.1007/s11481-024-10142-w. Epub 2024 Jul 23. PMID: 39042202.
* Bliddal H, Bays H, Czernichow S, Uddén Hemmingsson J, Hjelmesæth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Vélez Sánchez P, Wharton S, Wizert A, Kristensen LE, STEP 9 Study Group. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664. PMID: 39476339.
* Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. PMID: 40544433.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.